Construction and immunogenicity of an mRNA vaccine against chikungunya virus

Frontiers in Immunology

Immunology

Bo Ying¹  Xishan Lu¹  Haifeng Song¹  Wenjuan Li²  Xingxing Li²  Minglei Liu²  Ming Li²  Jia Li²  Zelun Zhang²  Enyue Fang²  Xiaohui Liu²  Weijin Huang³  Jingjing Liu⁴  Yuhua Li⁴ 

[1] Department of Preclinical Vaccine Research, Suzhou Abogen Biosciences Co., Ltd., Suzhou, China;Division of Arboviral Vaccines, National Institutes for Food and Drug Control, Beijing, China;Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China;State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China;Division of Arboviral Vaccines, National Institutes for Food and Drug Control, Beijing, China;

关键词: chikungunya virus;    mRNA vaccine;    immunogenicity;    sequential immunization;    prime-boost;   

DOI  :  10.3389/fimmu.2023.1129118

 received in 2022-12-21, accepted in 2023-02-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

Chikungunya fever (CHIKF) has spread to more than 100 countries worldwide, with frequent outbreaks in Europe and the Americas in recent years. Despite the relatively low lethality of infection, patients can suffer from long-term sequelae. Until now, no available vaccines have been approved for use; however, increasing attention is being paid to the development of vaccines against chikungunya virus (CHIKV), and the World Health Organization has included vaccine development in the initial blueprint deliverables. Here, we developed an mRNA vaccine using the nucleotide sequence encoding structural proteins of CHIKV. And immunogenicity was evaluated by neutralization assay, Enzyme-linked immunospot assay and Intracellular cytokine staining. The results showed that the encoded proteins elicited high levels of neutralizing antibody titers and T cell-mediated cellular immune responses in mice. Moreover, compared with the wild-type vaccine, the codon-optimized vaccine elicited robust CD8+ T-cell responses and mild neutralizing antibody titers. In addition, higher levels of neutralizing antibody titers and T-cell immune responses were obtained using a homologous booster mRNA vaccine regimen of three different homologous or heterologous booster immunization strategies. Thus, this study provides assessment data to develop vaccine candidates and explore the effectiveness of the prime-boost approach.

【 授权许可】

Unknown   
Copyright © 2023 Liu, Lu, Li, Huang, Fang, Li, Liu, Liu, Li, Li, Zhang, Song, Ying and Li